Compare MDXH & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MDXH | FLYX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 62.1M |
| IPO Year | 2021 | 2021 |
| Metric | MDXH | FLYX |
|---|---|---|
| Price | $0.69 | $1.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 16.3M | 287.0K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $375,877,000.00 |
| Revenue This Year | $30.78 | $10.47 |
| Revenue Next Year | $18.31 | $15.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.40 | $1.05 |
| 52 Week High | $5.33 | $8.88 |
| Indicator | MDXH | FLYX |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 41.42 |
| Support Level | $0.68 | $1.13 |
| Resistance Level | $1.13 | $1.36 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 12.58 | 18.52 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.